Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1
Author(s) -
Susanggie,
Curtis Cooper,
Michael S. Saag,
Kimberly Workowski,
Peter Ruane,
William Towner,
Kristen Marks,
Anne F. Luetkemeyer,
Rachel Baden,
Paul E. Sax,
Edward Gane,
Jorge SantanaBagur,
Luisa M. Stamm,
Jenny C. Yang,
Polina German,
Hadas DvorySobol,
Liyun Ni,
Phillip S. Pang,
John G. McHutchison,
Catherine Stedman,
Javier O Morales-Ramirez,
Norbert Bräu,
Dushyantha Jayaweera,
Amy E. Colson,
Pablo Tebas,
David Wong,
Douglas T. Dieterich,
Mark Sulkowski
Publication year - 2015
Publication title -
new england journal of medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 19.889
H-Index - 1030
eISSN - 1533-4406
pISSN - 0028-4793
DOI - 10.1056/nejmoa1501315
Subject(s) - medicine , ledipasvir , sofosbuvir , adverse effect , efavirenz , gastroenterology , hepatitis c virus , emtricitabine , regimen , hepatitis c , raltegravir , cirrhosis , viral load , virology , human immunodeficiency virus (hiv) , ribavirin , virus , antiretroviral therapy
Effective treatment for hepatitis C virus (HCV) in patients coinfected with human immunodeficiency virus type 1 (HIV-1) remains an unmet medical need.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom